uniQure (NASDAQ:QURE) Releases Earnings Results, Beats Expectations By $0.21 EPS

uniQure (NASDAQ:QURE) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21, Zacks reports. uniQure had a negative return on equity of 158.09% and a negative net margin of 1,027.52%. The firm had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million.

uniQure Stock Performance

QURE traded up $0.38 on Thursday, reaching $7.54. The company had a trading volume of 761,926 shares, compared to its average volume of 1,411,609. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $11.35. The stock has a market cap of $367.20 million, a P/E ratio of -1.27 and a beta of 0.90. The company’s fifty day moving average is $5.70 and its 200 day moving average is $5.79. The company has a debt-to-equity ratio of 1.06, a quick ratio of 7.36 and a current ratio of 7.36.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 target price on shares of uniQure in a report on Wednesday. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of uniQure in a report on Wednesday. StockNews.com raised shares of uniQure to a “sell” rating in a research note on Thursday, October 17th. Raymond James restated an “outperform” rating and set a $20.00 target price on shares of uniQure in a report on Thursday, October 10th. Finally, Royal Bank of Canada decreased their price target on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Wednesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $17.00.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.